Implements oral fluid tests which tests a person's saliva for the presence of cannabis.
Implements oral fluid tests which tests a person's saliva for the presence of cannabis.
Relates to saliva swabs and chemical tests in certain cases.
Provides that every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or diagnostic X-rays shall provide coverage for testing of familial dysautonomia, Canavan's disease and Tay-Sachs; provides that in order to maintain the confidentiality of persons tested, receipt of acknowledgement from the testing facility shall be deemed sufficient evidence of testing.
Provides that every policy which provides coverage for hospital, surgical or medical care or provides reimbursement for laboratory tests or diagnostic X-rays shall provide coverage for testing of familial dysautonomia, Canavan's disease and Tay-Sachs; provides that in order to maintain the confidentiality of persons tested, receipt of acknowledgement from the testing facility shall be deemed sufficient evidence of testing.
Requires development and implementation of a comprehensive education campaign regarding the dangers of cannabinoid use.
Relates to employee or prospective employee testing for the presence of tetrahydrocannabinols or marihuana as a condition of employment.
Requires pre-employment investigation of school district personnel to determine criminal history or the presence of controlled substances or communicable diseases; requires submission to fingerprinting and other tests.
Relates to cannabinoid hemp and hemp extract; defines terms; provides that any orally consumed product in the form of a beverage and containing cannabinoids derived only from hemp, including cannabinoid hemp or hemp extract, with .5 milligrams or greater of total THC per container may not be sold to individuals under twenty-one years of age.
Relates to notice of certain medical options and to communication with the person being tested prior to HIV related testing.